Pipeline
.....
Development Pipeline
Advancing regenerative medicine through innovative homeoprotein-based therapies.
Homeoprotein (HP)-Based Therapeutic Platform
Advancing innovative therapies through two complementary homeoprotein
strategies to restore tissue function and unlock natural regeneration.
Strategy 01
Remove Bad HPs
Neutralizing harmful homeoproteins
that accumulate after tissue injury
and suppress endogenous
regeneration pathways.
- CLZ001-Wet-AMD
- CLZ002-Retinitis Pigmentosa
- CLZ003-Dry-AMD
- CLZ003-Alzheimer’s Disease
Strategy 02
Provide Good HPs
Directly delivering essential
regenerative homeoproteins
to tissues degenerating due to
homeoprotein deficiencies.
- CLZ005: Muscle Regeneration
- CLZ006: Hair Cell Regeneration
- CLZ007: Corneal Regeneration
Research & Development Pipeline
Advancing regenerative medicine through innovative homeoprotein-based therapies.
CLZ001
Wet-type Age-related Macular Degeneration (Wet-AMD)
Lead Optimization
Optimizing candidate antibody for preclinical development.
40%
CLZ002
Retinitis Pigmentosa
(RP)
Preclinica
Large animal efficacy tests & GLP-
toxicity tests prior to IND filing for
first-in-human clinical trials
60%
CLZ005
Muscle
Regeneration
Target Validation
Identifying and validating
initial antibody hits.
20%
CLZ006
Hair Cell
Regeneration
Target Validation
Identifying and validating
initial antibody hits.
20%
CLZ007
Corneal
Regeneration
Target Validation
Identifying and validating
initial antibody hits.
20%
Expanding Scalable Horizons
Celliaz is building a scalable regenerative medicine platform with applications spanning ophthalmology, neurodegeneration,
and future tissue regeneration opportunities.
Our proprietary technologies and global intellectual property portfolio provide a strong foundation for future licensing,
co-development, and strategic partnerships.
Ophthalmology
Core Therapeutic Area
Neurodegenerative Diseases
Expansion Area
Strategic Partnerships
Business Development